PYREXAR
PYREXAR Medical
PYREXAR Medical is the pioneer and worldwide market leader in the development and manufacturing of innovative and highly effective hyperthermia treatment systems with established global distribution. PYREXAR Hyperthermia treatments increase the effective dose of ionizing radiation in cancerous tumors up to 3X without increasing toxicity in healthy tissues.
PYREXAR HT systems deliver therapeutic heating to cancerous tumors via non-invasive radio-frequency (RF) energy. Cancer cells are hypoxic and have a low pH, making them more susceptible to the increased temperature. During the HT treatment, the solid tumor micro-environment is warmed to ~ 42˚C (108˚F) to assist in the destruction of malignant cells while preserving healthy tissues.
PYREXAR HT systems deliver therapeutic heating to cancerous tumors via non-invasive radio-frequency (RF) energy. Cancer cells are hypoxic and have a low pH, making them more susceptible to the increased temperature. During the HT treatment, the solid tumor micro-environment is warmed to ~ 42˚C (108˚F) to assist in the destruction of malignant cells while preserving healthy tissues.
BSD-2000 3D/MR Deep Regional Hyperthermia
MR image guided real-time non-invasive thermometry and Integration with 1.5 Tesla MR system
View Details
BSD-2000/2000 3D Deep Regional Hyperthermia
Deep Regional system using an annular phased array configuration to shape and focus thermal energy on targeted treatment area deep inside the limbs, pelvis, abdomen or thorax.
View Details
BSD-500 Superficial Hyperthermia
BSD-500 Superficial Hyperthermia is a versatile, fully self-contained treatment system in a mobile configuration or maximum treatment flexibility of superficial tumours within 1” of skin surface.
View Details
Get in Touch
Let’s Advance Care, Together
Whether you’re a healthcare provider, distributor, or medical institution, we’re here to support you with cutting-edge, non-invasive cancer treatment technologies.
Our team is ready to answer your questions, provide detailed product insights, or discuss partnership opportunities.